Immatics N.V.
IMTXHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeImmatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. With a market capitalization of $1.11B, it sits in small-cap territory. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Market Cap
$1.11B
Beta
1.36
P/E (TTM)
—
P/E (Fwd)
-3.61
EPS (TTM)
$-1.87
EPS (Fwd)
$-2.03
ROE
-47.8%
ROA
-26.9%
Cash
$393.4M
Total Debt
$14.6M
Free CF
-$126.5M
52W Change
-28.2%
Annual Financials
Cash vs Debt
Where IMTX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, IMTX finished 26.87% below its 150-day moving average ($9.64) and 27.24% below its 200-day moving average ($9.69). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IMTX overbought or oversold?
At the October 20, 2026 close, IMTX's RSI(14) was 29.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $393.4M in cash and $14.6M in debt, IMTX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$126.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -47.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $172.8M (2022) to $48.3M (2025), a 72% decline worth watching.
With cash comfortably exceeding debt, IMTX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Immatics N.V. and its sector.